OC-0503: Weekly vs. every-other-day prostate cancer SBRT: 18-months results from a randomized phase II trial. (April 2018) - Zilli, T.; Jorcano, S.; Bral, S.; Rubio, C.; Bruynzeel, A.; Oliveira, A.; Abacioglu, U.; Minn, H.; Symon, Z.; Miralbell, R.